Say goodbye to the era of "high doses"! How does Tenofovir Amibufenamide achieve highly effective antiviral effects with only 1/10 of the dose?
01/13/2026 Written by DengyueMed Tenofovir Amibufenamide (Hengmu®) is a next-generation tenofovir prodrug independently developed in China for the treatment of chronic hepatitis B (CHB). Designed with optimized molecular structure and enhanced liver targeting, Tenofovir Amibufenamide delivers potent antiviral efficacy at a significantly lower dose, while offering a favorable long-term...
0 Commentarii 0 Distribuiri 4 Views 0 previzualizare